Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RPCAR01 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on RPCAR01, a putative T-cell therapy targeting GPC3 (Jun 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RPCAR01 | RPCAR-01|RPCAR 01 | GPC3 Immune Cell Therapy 8 | Limited information is currently available on RPCAR01, a putative T-cell therapy targeting GPC3 (Jun 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06968195 | Phase I | RPCAR01 Cyclophosphamide + Fludarabine | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma | Suspended | USA | 0 |